Ablative Radiotherapy as a Strategy to Overcome TKI Resistance in EGFR-Mutated NSCLC.

Area of Science:

• Oncology
• Radiation Oncology
• Medical Physics

Background:

• Tyrosine kinase inhibitor (TKI) therapy is the standard first-line treatment for metastatic non-small-cell lung cancer (NSCLC) with EGFR mutations.
• Acquired resistance to TKI therapy is a significant challenge in managing EGFR-mutant NSCLC, necessitating novel therapeutic strategies.

Purpose of the Study:

• To review existing literature on the use of local ablative radiation therapy for acquired TKI resistance in EGFR-mutant NSCLC.
• To discuss the potential of stereotactic radiation therapy (SBRT/SRS) as a strategy to overcome TKI resistance.

Main Methods:

• Literature review of studies investigating local ablative radiation therapy in the context of acquired TKI resistance.
• Analysis of clinical trials exploring SBRT/SRS for progressive disease during TKI therapy.

Main Results:

• The review focuses on the efficacy and safety of SBRT/SRS in managing TKI-resistant EGFR-mutant NSCLC.
• Ongoing clinical trials are evaluating stereotactic radiation therapy as a method to overcome TKI resistance.

Conclusions:

• Stereotactic radiation therapy (SBRT/SRS) represents a promising strategy to overcome acquired resistance to TKI therapy in EGFR-mutant NSCLC.
• Further research and clinical trials are essential to establish the role of SBRT/SRS in managing TKI-resistant NSCLC.